Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Mediar Therapeutics has raised $85.0M in total funding. The most recent round was Series A. The last funding was announced in March 2023.
Mediar Therapeutics's investors include Bristol-Myers Squibb, Sofinnova Partners, Mission BioCapital, Pureos Bioventures, Novartis Venture Fund.
Mediar Therapeutics is headquartered in Cambridge, United States.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Mediar Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mediar Therapeutics — Funding & Investors." VCBacked, March 15, 2023, https://www.vcbacked.co/company/mediar-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Mediar Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/mediar-therapeutics
{{cite web |title=Mediar Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mediar-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated